Trial Profile
ELUXA 6: Phase II study of olmutinib in patients with EGFR T790M mutation-positive NSCLC
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2016
Price :
$35
*
At a glance
- Drugs Olmutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 21 Jun 2016 New trial record